博士研究生导师
药理学-王韵

2EA0E

王韵,女,博士,教授,博士研究生导师,药学院临床药理学党支部书记。现任辽宁省细胞生物学学会呼吸生理专业委员会理事、辽宁省细胞生物学学会泌尿系肿瘤化学生物治疗和细胞学研究专业委员会常务理事。2017-2018年在美国University of Texas, Health Science Center at Tyler进行访问学习。研究方向为心脑肺血管药理学,目前主要从事肺动脉高压和肺损伤机制的研究。承担并主持国家自然科学基金2项、省级课题3,发表研究论文三十余教育部自然科学二等奖1辽宁省科技进步二等奖22014,第二获奖人)和辽宁省自然科学学术成果二等奖1项(2019,第一获奖人)。指导的研究生获得辽宁省普通高等学校优秀毕业生、校优秀毕业研究生、中国医科大学研究生国家奖学金、药学院兴齐眼药豪森医药药学特等奖励基金、提名中国医科大学优秀硕士学位论文等荣誉称号。作为副主编、编委参与多部国家级规划教材的编写,如高等教育出版社《临床药理学》 (副主编)、吉林科技出版社《实用药物治疗学》(副主编)、人民卫生出版社《药理学》(编委)、中国医药科技出版社《药事管理学》(编委)等多部全国高等医药院校规划教材。

电子邮箱:ywang28@cmu.edu.cn

研究方向

1.心脑肺血管药理学,目前主要从事肺动脉高压和肺损伤机制的研究

2.药物毒理学药物滥用致器官毒性机制研究

二、承担与参与课题:

1.国家自然科学基金面上项目(No. 81973404),主持人

2.国家自然科学基金青年项目(No. 81503058),主持

3.辽宁省自然科学基金面上项目(No. 2022-MS-224),主持人

4.辽宁省自然科学基金面上项目(No. 2014021065),主持

5.辽宁省教育厅基础研究项目(No. JC2019034),主持

三、奖励及荣誉:

1.2019年,辽宁省自然科学学术成果二等奖(第一获奖人)

2.2018年,辽宁省自然科学学术成果三等奖(第一获奖人)

3.2014年,获辽宁省科技进步二等奖1项(第二获奖人)

4.2010年,获国家教育部自然科学二等奖1

5.2009年,获辽宁省科技进步二等奖1

6.2017年,获得中国医科大学兴齐眼药药学奖励基金中青年教师一等奖

7.培养研究生曾获“辽宁省普通高等学校优秀毕业生”、“中国医科大学研究生国家奖学金”、“豪森兴齐眼药药学奖励基金一等奖”等荣誉称号。

四、近5年发表SCI论文(通讯作者*

1.Chen L, Gu YJ, Zhang XG, Cheng L, Zhou MY, Yang Y, Wang Y*. Macrophage microvesicles-derived circ_YTHDF2 in methamphetamine-induced chronic lung injury. J Physiol. 2023 Apr 20. doi: 10.1113/JP284086. Online ahead of print. PMID: 37078283

2.Guo C, Chen L, Wang Y*. Substance abuse and neurodegenerative diseases: focus on ferroptosis. Arch Toxicol. 2023 Jun;97(6):1519-1528. doi: 10.1007/s00204-023-03505-4. Epub 2023 Apr 26. PMID: 37100932 Review.

3.Fu YP, Wang Y*. Amphetamines abuse and depression: Focus on TRPC channels. Exp Neurol. 2023 Jun;364:114391. doi: 10.1016/j.expneurol.2023.114391. Epub 2023 Mar 28. PMID: 36996966

4.Pang L, Wang Y*. Overview of blood-brain barrier dysfunction in methamphetamine abuse. Biomed Pharmacother. 2023 May; 161:114478. doi: 10.1016/j.biopha.2023.114478. Epub 2023 Mar 14. PMID: 37002574. Review.

5.Yang Y, Wang Y*. Autocrine, Paracrine, and Endocrine Signals That Can Alter Alveolar Macrophages Function. Rev Physiol Biochem Pharmacol. 2022 Dec 7. doi: 10.1007/112_2022_76. Online ahead of print. PMID: 36472676

6.Ma PJ, Wang MM, Wang Y*. Gut microbiota: A new insight into lung diseases. Biomed Pharmacother. 2022 Nov; 155:113810. doi: 10.1016/j.biopha.2022.113810. Epub 2022 Oct 8.

7.Zhang Y, Wang Y*. Cell-to-Cell Crosstalk: A New Insight into Pulmonary Hypertension. Rev Physiol Biochem Pharmacol. 2022 Apr 6. doi: 10.1007/112_2022_70. Online ahead of print. PMID: 35380274

8.Liu L, Liu M, Zhao W, Zhao YL, Wang Y*. Tetrahydropalmatine Regulates BDNF through TrkB/CAM Interaction to Alleviate the Neurotoxicity Induced by Methamphetamine. ACS Chem Neurosci. 2021 Sep 15;12(18):3373-3386. doi: 10.1021/acschemneuro.1c00373. Epub 2021 Aug 27

9.Liu L, Liu M, Zhao W, Zhao YL, Wang Y*. Levo-tetrahydropalmatine: A new potential medication for methamphetamine addiction and neurotoxicity. 2021 Oct; 344:113809. doi: 10.1016/j.expneurol.2021.113809. Epub 2021 Jul 10. Exp Neurol. PMID: 34256045.

10.Zhao YL, Zhao W, Liu M, Liu L, Wang Y*. TBHQ-Overview of Multiple Mechanisms against Oxidative Stress for Attenuating Methamphetamine-Induced Neurotoxicity. Oxid Med Cell Longev. 2020 Nov 27; 2020:8874304. doi:10.1155/2020/8874304. eCollection 2020.

11.Wang X, Liu M, Zhu MJ, Shi L, Liu L, Zhao YL, Cheng L, Gu YJ, Zhou MY, Chen L, Kumar A, Wang Y*. Resveratrol Protects the Integrity of Alveolar Epithelial Barrier via SIRT1/PTEN/p-Akt Pathway in Methamphetamine-Induced Chronic Lung Injury. Cell Prolif. 2020 Mar; 53(3):e12773. doi: 10.1111/cpr.12773. Epub 2020 Feb 5.

12.Zhu MJ, Liu BY, Shi L, Wang X, Wang Y*. mTOR-autophagy promotes pulmonary senescence through IMP1 in chronic toxicity of methamphetamine. J Cell Mol Med. 2020 Oct;24(20):12082-12093. doi: 10.1111/jcmm.15841. Epub 2020 Sep 11.

13.Wang Y, Hao Q, Florence JM, Jung BG, Kurdowska AK, Samten B, Idell S, Tang H*. Influenza Virus Infection Induces ZBP1 Expression and Necroptosis in Mouse Lungs. Front Cell Infect Microbiol. 2019 Aug 7; 9:286. doi: 10.3389/fcimb.2019.00286. eCollection 2019.

14.Wang Y*, Gu YH, Liang LY, Liu M, Jiang B, Zhu MJ, Wang X, Shi L. Concurrence of autophagy with apoptosis in alveolar epithelial cells contributes to chronicpulmonary toxicity induced by methamphetamine. Cell Prolif. 2018 Jun 28:e12476. doi: 10.1111/cpr.12476. [Epub ahead of print]

15.Wang Y*, Gu YH, Liu M, Bai Y, Liang LY, Wang HL. TBHQ Alleviated Endoplasmic Reticulum Stress-Apoptosis and Oxidative Stress by PERK-Nrf2 Crosstalk in Methamphetamine-Induced Chronic Pulmonary Toxicity. Oxid Med Cell Longev. 2017; 2017:4310475.

16.Chen L, Gu YJ, Zhou MY, Cheng L, Wang Y*. Microvesicles-mediated Cell Communication in Pulmonary Arterial Hypertension. Curr Med Chem. 2021;28(23):4731-4741. doi: 10.2174/0929867328666201124152406. Online ahead of print. PMID: 33234089. epub 2020 Nov 24.

17.Gu YJ, Chen L, Cheng L, Zhou MY, Wang Y*. Non-coding RNA: insights into the mechanism of methamphetamine neurotoxicity. Mol Cell Biochem. 2021 Sep;476(9):3319-3328. doi: 10.1007/s11010-021-04160-y. Online ahead of print. PMID: 33895910 Review.

18.Cheng L, Zhou MY, Gu YJ, Chen L, Wang Y*. ZEB1: New advances in fibrosis and cancer. Mol Cell Biochem. 2021 Apr;476(4):1643-1650. doi: 10.1007/s11010-020-04036-7. Epub 2021 Jan 8.

19.Shi L, Liu BY, Wang X, Zhu MJ, Chen L, Zhou MY, Gu YJ, Cheng L, Wang Y*. RUNX3-dependent oxidative epithelial-to-mesenchymal transition in methamphetamine-induced chronic lung injury. Cell Stress Chaperones. 2020 Jul 17; 25(5):793-802. doi: 10.1007/s12192-020-01133-w.

20.Liang LY, Wang MM, Liu M, Zhao W, Wang X, Shi L, Zhu MJ, Zhao YL, Liu L, Maurya P, Wang Y*. Chronic toxicity of methamphetamine: Oxidative remodeling of pulmonary arteries. Toxicol In Vitro. 2020 Feb; 62:104668. doi: 10.1016/j.tiv.2019.104668. Epub 2019 Oct 16.

21.Gu YH, Wang Y*, Bai Y, Liu M, Wang HL. Endoplasmic reticulum stress and apoptosis via PERK-eIF2α-CHOP signaling in the methamphetamine-induced chronic pulmonary injury. Environ Toxicol Pharmacol. 2017 Jan; 49:194-201.

22.Zhou MY, Cheng L, Chen L, Gu YJ, Wang Y*. Calcium-sensing receptor in the development and treatment of pulmonary hypertension. Mol Biol Rep. 2021 Jan; 48(1):975-981. doi: 10.1007/s11033-020-06065-3. Online ahead of print.

五、近5年教材编写:

1.副主编,《临床药理学》,高等教育出版社,2020.

2.副主编,《临床药物治疗学》,吉林科技出版社,2018.

3.编委,《药事管理学》,中国医药科技出版社,2021.

4.编委,《药理学》,人民卫生出版社,2019.

5.编委,《临床药物治疗学》,上海科学技术出版社,2017.